About Us
We are a translational medicine company focused on bringing innovative science to market. We are developing a monoclonal antibody therapy, namilumab (IZN-101), targeting granulocyte macrophagecolony stimulating factor (GM-CSF).
IZN-101 is under investigation for its use against the ongoing COVID-19 pandemic, to halt the rapid deterioration of patients with acute respiratory distress.
IZN-101 is also in development for the treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS), a debilitating arthritic disease with no cure. IZN-101 has demonstrated its efficacy in a Phase IIb study in RA (NEXUS) and is a potential novel treatment, with a novel mode of action.
Investors and Collaborators
Izana Bioscience has partners who share our commitment to developing IZN-101 for the benefit of patients
Our Team
Izana Bioscience is led by an experienced management team and supported by a world class clinical advisory board
Prof. Bryan Morton CBE
Chairman
Founded EUSA Pharma - sold to Jazz Pharmaceuticals for $700m
Founded Zeneus Pharma - sold to Cephalon for $360m
Read more
Dr. Someit Sidhu
Chief Executive Officer
BM BCh, Oxon
McKinsey & Company, Pharmaceuticals and Medical Products practice
Read more
Dr. Tim Corn
Chief Medical Officer
Former CMO of EUSA Pharma & Zeneus
Former Senior Executive Elan, GSK
More than 20 regulatory approvals in US and EU
Read more
Contact Us
Send us an email using the form and one of the team will be in touch with you soon.